Population pharmacokinetics and dose rationale for aciclovir in term and pre-term neonates with herpes.

ABSTRACT: Aciclovir is considered the first-line treatment against Herpes simplex virus (HSV) infections in new-borns and infants. As renal excretion is the major route of elimination, in renally-impaired patients, aciclovir doses are adjusted according to the degree of impairment. However, limited attention has been given to the implications of immature renal function or dysfunction due to the viral disease itself. The aim of this investigation was to characterize the pharmacokinetics of aciclovir taking into account maturation and disease processes in the neonatal population. Pharmacokinetic data obtained from 2 previously published clinical trials (n = 28) were analyzed using a nonlinear mixed effects modeling approach. Post-menstrual age (PMA) and creatinine clearance (CL_CR) were asse

SUBMITTER: D'Agate S 

PROVIDER: S-EPMC11110484 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature